CARBIOS files its 2024 Universal Registration Document Clermont-Ferrand (France), May 2, 2025 (6:00 pm CEST). , (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces to its shareholders and the financial community that its 2024 Universal Registration Document including the annual report, the management report and the report on corporate governance was filed with the French Financial Market Authority (Autorité des marchés financiers) on April 30, 2025 under the number D.25-0...
CARBIOS annonce la mise à disposition de son Document d’enregistrement universel 2024 Clermont-Ferrand (France), le 2 mai 2025 (18h00 CEST). (Euronext Growth Paris : ALCRB), pionnière dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de vie des plastiques et des textiles, informe ses actionnaires et l’ensemble de la communauté financière que son Document d’enregistrement universel 2024, incluant le rapport annuel, le rapport de gestion et le rapport sur le gouvernement d’entreprise 2024, a été déposé auprès de l’Autorité des Marchés Financi...
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.